As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

Non-small cell lung cancers (NSCLCs) represent 85% of lung tumors. NSCLCs encompass
multiple cancer types, such as adenocarcinomas (LUADs), squamous cell cancers (LUSCs) …

PURPOSE Hormone receptor–positive (HR+) human epidermal growth factor receptor 2–
negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential …

Background Sacituzumab govitecan demonstrated significant progression-free survival
benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated …

Background The pivotal phase III ASCENT trial demonstrated improved survival outcomes
associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti …

Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed
antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by …

Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a
potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug …

TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but
subsequently shown to be increased in many solid cancers, with lower expression in certain …

Trop2 is a transmembrane glycoprotein and calcium signal transducer with limited
expression in normal human tissues. It is consistently overexpressed in a variety of …

Trop-2 is a novel target for ADC therapy because of its high expression by many solid
cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that …